Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Phase 3 Delay

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Jun 30, 2021 1:21pm

153 Views

Post# 33473834

RE:Phase 3 Delay

Slightly delay is okay for me. We have already known that PIII will be a successful one - it is only a matter of time. Plus, I am not so eager to retire - working from home is kind of similar to vactaion to me ...... receive pay cheques with the same decent amount but save on time and commute expenses ...... it is okay for me ...... I have enough patient to wait for my big prize from ATE.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023